Literature DB >> 18339850

Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25.

Mathewos Tessema1, Randy Willink, Kieu Do, Yang Y Yu, Wayne Yu, Emi O Machida, Malcolm Brock, Leander Van Neste, Christine A Stidley, Stephen B Baylin, Steven A Belinsky.   

Abstract

Chromosomal aberrations associated with lung cancer are frequently observed in the long arm of chromosome 6. A candidate susceptibility locus at 6q23-25 for lung cancer was recently identified; however, no tumor suppressor genes inactivated by mutation have been identified in this locus. Genetic, epigenetic, gene expression, and in silico screening approaches were used to select 43 genes located in 6q12-27 for characterization of methylation status. Twelve (28%) genes were methylated in at least one lung cancer cell line, and methylation of 8 genes was specific to lung cancer cell lines. Five of the 8 genes with the highest prevalence for methylation in cell lines (TCF21, SYNE1, AKAP12, IL20RA, and ACAT2) were examined in primary lung adenocarcinoma samples from smokers (n = 100) and never smokers (n = 75). The prevalence for methylation of these genes was 81%, 50%, 39%, 26%, and 14%, respectively, and did not differ by smoking status or age at diagnosis. Transcription of SYNE1, AKAP12, and IL20RA was completely silenced by hypermethylation and could be restored after treatment with 5-aza-2-deoxycytidine. Significant associations were found between methylation of SYNE1 and TCF21, SYNE1 and AKAP12, and AKAP12 and IL20RA, indicating a coordinated inactivation of these genes in tumors. A higher prevalence for methylation of these genes was not associated with early-onset lung cancer cases, most likely precluding their involvement in familial susceptibility to this disease. Together, our results indicate that frequent inactivation of multiple candidate tumor suppressor genes within chromosome 6q likely contributes to development of sporadic lung cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18339850     DOI: 10.1158/0008-5472.CAN-07-6325

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

Review 1.  Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12.

Authors:  Irwin H Gelman
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

2.  Protein expression and promoter methylation of the candidate biomarker TCF21 in gastric cancer.

Authors:  Z Yang; D M Li; Q Xie; D Q Dai
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-26       Impact factor: 4.553

3.  Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression.

Authors:  Laila H Faraj Shaglouf; Maryam Ranjpour; Saima Wajid; Swatantra Kumar Jain
Journal:  Protoplasma       Date:  2019-08-19       Impact factor: 3.356

4.  Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.

Authors:  Steven A Belinsky; Marcie J Grimes; Maria A Picchi; Hugh D Mitchell; Chris A Stidley; Yohannes Tesfaigzi; Meghan M Channell; Yanbin Liu; Robert A Casero; Stephen B Baylin; Mathew D Reed; Carmen S Tellez; Thomas H March
Journal:  Cancer Res       Date:  2011-01-11       Impact factor: 12.701

Review 5.  Expanding the repertoire of deadenylases.

Authors:  Ilias Skeparnias; Dimitrios Αnastasakis; Athanasios-Nasir Shaukat; Katerina Grafanaki; Constantinos Stathopoulos
Journal:  RNA Biol       Date:  2017-03-07       Impact factor: 4.652

6.  GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.

Authors:  Mathewos Tessema; Christin M Yingling; Amanda M Snider; Kieu Do; Daniel E Juri; Maria A Picchi; Xiequn Zhang; Yushi Liu; Shuguang Leng; Carmen S Tellez; Steven A Belinsky
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

7.  ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.

Authors:  Jennifer A Doherty; Mary Anne Rossing; Kara L Cushing-Haugen; Chu Chen; David J Van Den Berg; Anna H Wu; Malcolm C Pike; Roberta B Ness; Kirsten Moysich; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Jenny Chang-Claude; Shan Wang-Gohrke; Marc T Goodman; Galina Lurie; Pamela J Thompson; Michael E Carney; Estrid Hogdall; Susanne Kruger Kjaer; Claus Hogdall; Ellen L Goode; Julie M Cunningham; Brooke L Fridley; Robert A Vierkant; Andrew Berchuck; Patricia G Moorman; Joellen M Schildkraut; Rachel T Palmieri; Daniel W Cramer; Kathryn L Terry; Hannah P Yang; Montserrat Garcia-Closas; Stephen Chanock; Jolanta Lissowska; Honglin Song; Paul D P Pharoah; Mitul Shah; Barbara Perkins; Valerie McGuire; Alice S Whittemore; Richard A Di Cioccio; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Susan J Ramus; Argyrios Ziogas; Wendy Brewster; Hoda Anton-Culver; Celeste Leigh Pearce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

8.  Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma.

Authors:  Daniel Weiss; Christian Stockmann; Katrin Schrödter; Claudia Rudack
Journal:  Cell Oncol (Dordr)       Date:  2013-03-26       Impact factor: 6.730

9.  Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis.

Authors:  M Tessema; D M Klinge; C M Yingling; K Do; L Van Neste; S A Belinsky
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

Review 10.  Epigenetics: connecting environment and genotype to phenotype and disease.

Authors:  S P Barros; S Offenbacher
Journal:  J Dent Res       Date:  2009-05       Impact factor: 6.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.